AVROBIO INC (AVRO) Stock Price, Quote, News and Overview
NASDAQ:AVRO - Nasdaq - US05455M1009 - Common Stock - Currency: USD
AVRO Quote, Performance and Key Statistics
1.4
-0.02 (-1.41%)
The current stock price of AVRO is 1.4 USD. In the past month the price increased by 1.45%. In the past year, price increased by 52.14%.
AVRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AVRO
Company Profile
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Company Info
AVROBIO INC
100 Technology Square, 6th Floor
Cambridge MASSACHUSETTS 02139 US
CEO: Geoff MacKay
Employees: 78
Company Website: https://www.avrobio.com/
Phone: 16179148420
AVROBIO INC / AVRO FAQ
What is the stock price of AVROBIO INC today?
The current stock price of AVRO is 1.4 USD. The price decreased by -1.41% in the last trading session.
What is the ticker symbol for AVROBIO INC stock?
The exchange symbol of AVROBIO INC is AVRO and it is listed on the Nasdaq exchange.
On which exchange is AVRO stock listed?
AVRO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVROBIO INC stock?
8 analysts have analysed AVRO and the average price target is 2.04 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 1.4. Check the AVROBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVROBIO INC worth?
AVROBIO INC (AVRO) has a market capitalization of 62.85M USD. This makes AVRO a Micro Cap stock.
How many employees does AVROBIO INC have?
AVROBIO INC (AVRO) currently has 78 employees.
What are the support and resistance levels for AVROBIO INC (AVRO) stock?
AVROBIO INC (AVRO) has a support level at 1.39 and a resistance level at 1.51. Check the full technical report for a detailed analysis of AVRO support and resistance levels.
Should I buy AVROBIO INC (AVRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVRO, evaluating the profitability, health, valuation and growth aspects
- AVROBIO INC (AVRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVROBIO INC (AVRO) Sales and EPS estimates to see what analysts future expectations are.
- AVROBIO INC (AVRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVROBIO INC (AVRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVROBIO INC (AVRO) Stock Chart to make your own analysis
- AVROBIO INC (AVRO) Latest news and press-releases to stay up to date.
Does AVROBIO INC (AVRO) stock pay dividends?
AVRO does not pay a dividend.
When does AVROBIO INC (AVRO) report earnings?
AVROBIO INC (AVRO) will report earnings on 2024-08-08, after the market close.
What is the Price/Earnings (PE) ratio of AVROBIO INC (AVRO)?
AVROBIO INC (AVRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
AVRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AVRO. When comparing the yearly performance of all stocks, AVRO is one of the better performing stocks in the market, outperforming 92.57% of all stocks.
AVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVRO. AVRO has a great financial health rating, but its profitability evaluates not so good.
AVRO Financial Highlights
Over the last trailing twelve months AVRO reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 49.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 32.82% | ||
| ROE | 34.11% | ||
| Debt/Equity | 0 |
AVRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to AVRO. The Buy consensus is the average rating of analysts ratings from 8 analysts.